A Case of Severe Liver Dysfunction During the Administration of Alectinib
Tetsuo Tani(Keio University), Hidefumi Koh(Tachikawa Hospital), Keeya Sunata(Keio University), Takahiro Fukui(Tachikawa Hospital), Yohei Funatsu(Keio University), Kotaro Kaneko(Tachikawa Hospital)
Cited by 0
Related Papers
<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer
|Oncotarget|2015|159
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
|Cancer Cell|2022|101
<i>TREX1</i> Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor Immunity
|Cancer Discovery|2024|98
Activation of Tumor-Cell STING Primes NK-Cell Therapy
|Cancer Immunology Research|2022|88
Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer
|Molecular Cancer Research|2016|73